Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.76 |
| ▸ | CA1 | P00915 | 5/20 | 0.63 |
| ▸ | CA2 | P00918 | 5/20 | 0.63 |
| ▸ | CA7 | P43166 | 5/20 | 0.63 |
| ▸ | CA9 | Q16790 | 5/20 | 0.63 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29364392 | 0.87 | KDR (1.00) | KDRCA1CA2CA7CA9 | |
| SCHEMBL118026 | 0.87 | KDR (1.00) | KDRCA1CA2CA7CA9 | |
| SCHEMBL13945722 | 0.85 | KDR (0.78) | KDRCA1CA2CA7CA9 | |
| SCHEMBL13004799 | 0.85 | KDR (0.82) | KDRCA1CA2CA7CA9 | |
| Cloflucarban SCHEMBL27537485 | 0.84 | KDR (0.88) | KDRCA1CA2CA7CA9 | |
| Cloflucarban SCHEMBL119821 | 0.84 | KDR (0.88) | KDRCA1CA2CA7CA9 | |
| SCHEMBL16620661 | 0.84 | KDR (0.72) | KDRCA1CA2CA7CA9 | |
| SCHEMBL620123 | 0.84 | KDR (0.67) | KDRCA1CA2CA7CA9 | |
| SCHEMBL14684324 | 0.83 | KDR (0.75) | KDRCA1CA2CA7CA9 | |
| SCHEMBL13969405 | 0.83 | KDR (0.70) | KDRCA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187696-B2 | Urea motif containing compounds and derivatives thereof as antibacterial drugs | Technische Universität München (DE) | 2025-01-07 | — | — | US | disclosed |
| EP-3464260-B1 | UREA MOTIF CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS ANTIBACTERIAL DRUGS | UNIV MUENCHEN TECH (DE) | 2021-10-27 | — | — | EP | disclosed |
| EP-3464260-B1 | UREA MOTIF CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS ANTIBACTERIAL DRUGS | UNIV MUENCHEN TECH (DE) | 2021-10-27 | — | — | EP | disclosed |
| US-20210009550-A1 | UREA MOTIF CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS ANTIBACTERIAL DRUGS | Technische Universität München (DE) | 2021-01-14 | — | — | US | disclosed |
| US-20210009550-A1 | UREA MOTIF CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS ANTIBACTERIAL DRUGS | Technische Universität München (DE) | 2021-01-14 | — | — | US | disclosed |
| US-20200138829-A1 | METHODS OF CANCER TREATMENT | Ferro Therapeutics, Inc. | 2020-05-07 | — | — | US | disclosed |
| CN-109890804-A | Compounds containing urea moieties and derivatives thereof as antibacterial agents | 慕尼黑工业大学 | 2019-06-14 | — | — | CN | disclosed |
| EP-3464260-A2 | UREA MOTIF CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS ANTIBACTERIAL DRUGS | Technische Universität München (DE) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017207556-A2 | UREA MOTIF CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS ANTIBACTERIAL DRUGS | Technische Universität München (DE) | 2017-12-07 | — | — | WO | disclosed |
| WO-2017207556-A2 | UREA MOTIF CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS ANTIBACTERIAL DRUGS | Technische Universität München (DE) | 2017-12-07 | — | — | WO | disclosed |
| WO-2015051149-A1 | SORAFENIB ANALOGS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-04-09 | — | — | WO | disclosed |
| WO-2015051149-A1 | SORAFENIB ANALOGS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-04-09 | — | — | WO | disclosed |
| US-20130065892-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-8329901-B2 | 4,6-disubstitued pyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20110230494-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110224432-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-7989465-B2 | 4,6-disubstituted pyrimidines useful as kinase inhibitors | AVILA THERAPEUTICS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065892-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | KDR 2602/4885CA1 4107/4885CA2 3325/4885 |
| US-20200138829-A1 | METHODS OF CANCER TREATMENT | AIFM2, GPX4, DDIT3 | KDR 4064/4885CA1 1120/4885CA2 1466/4885 |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | KDR 2602/4885CA1 4107/4885CA2 3325/4885 |
| US-20210009550-A1 | UREA MOTIF CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS ANTIBACTERIAL DRUGS | UMPS, UNG, UFM1 | KDR 3399/4885CA1 4624/4885CA2 4605/4885 |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | KDR 2602/4885CA1 4107/4885CA2 3325/4885 |
| US-20110224432-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | KDR 2602/4885CA1 4107/4885CA2 3325/4885 |
| US-12187696-B2 | Urea motif containing compounds and derivatives thereof as antibacterial drugs | UMPS, UNG, UFM1 | KDR 3399/4885CA1 4624/4885CA2 4605/4885 |
| US-20110230494-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | KDR 2602/4885CA1 4107/4885CA2 3325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.